Axxam and Lonza Announce the Signing of a License Agreement
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
Lonza and Axxam announced the signing of a license agreement enabling Lonza to include Axxam’s Photina®, i-Photina® and Clytin® Photoproteins as calcium biosensors in Lonza’s broad range of Clonetics® Primary Cells.
“We are really pleased to have entered this license agreement with Lonza”, says Sabrina Corazza, responsible for Business Development at Axxam. “It allows us to further validate and exploit our proprietary technology platform on photoproteins, and to address relevant market needs.”
“Enabling customers to easily perform assays in primary cells is a critical component of our primary cell strategy”, states Leon de Bruin, Senior Product Manager in Lonza’s Drug Discovery Marketing group. “Our newly introduced Clonetics® Primary Sensors range of products allows customers to access their primary cells of choice and measure endogenous receptor activity using the same technologies and protocols that they are used to using with over-expressing cell lines.”
Clonetics® Primary Sensors build on Lonza’s transfection capability to address the widely stated desire by researchers to measure drug targets in a biologically relevant environment. Well characterized primary cells are expanded to generate a sizeable and robust cell bank. The sensor is added to the cell using Lonza’s efficient Amaxa® Nucleofector® Technology and substrate is added before the cells are frozen. The customer receives a frozen, ready to use product.
“We are really pleased to have entered this license agreement with Lonza”, says Sabrina Corazza, responsible for Business Development at Axxam. “It allows us to further validate and exploit our proprietary technology platform on photoproteins, and to address relevant market needs.”
“Enabling customers to easily perform assays in primary cells is a critical component of our primary cell strategy”, states Leon de Bruin, Senior Product Manager in Lonza’s Drug Discovery Marketing group. “Our newly introduced Clonetics® Primary Sensors range of products allows customers to access their primary cells of choice and measure endogenous receptor activity using the same technologies and protocols that they are used to using with over-expressing cell lines.”
Clonetics® Primary Sensors build on Lonza’s transfection capability to address the widely stated desire by researchers to measure drug targets in a biologically relevant environment. Well characterized primary cells are expanded to generate a sizeable and robust cell bank. The sensor is added to the cell using Lonza’s efficient Amaxa® Nucleofector® Technology and substrate is added before the cells are frozen. The customer receives a frozen, ready to use product.
